<DOC>
	<DOCNO>NCT00696748</DOCNO>
	<brief_summary>The objective study assess effect testosterone therapy body composition , lipid glucose metabolism , inflammatory marker patient metabolic syndrome hypogonadism .</brief_summary>
	<brief_title>The Effect IM Testosterone Undecanoate Biochemical Anthropometric Characteristics Metabolic Syndrome Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>A sign informed consent participate study Men age 35 70 testosterone level 12 nmol/L free testosterone 225 pmol/L Presence metabolic syndrome accord IDF definition Patients 35 70 year . Participation clinical study within 30 day first injection drug Simultaneous participation another clinical study Incapable subject well prisoner Suspicion serious organic mental disease accord medical history and/or clinical examination Prostate cancer , breast cancer suspicion thereof Presence history hepatic tumor Acute chronic hepatic disease Presence renal disease renal failure Changes biochemical hematological laboratory value spite lack clinical manifestation , investigator 's opinion Suspected lack patient 's compliance Hypersensitivity active substance</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>metabolic syndrome</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone undecanoate</keyword>
</DOC>